Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis
Cette étude chinoise évalue l'association entre le niveau d'expression intratumorale de l'intélectine-1 humaine (une lectine nouvellement identifiée qui se lie spécifiquement au galactose), les caractéristiques clinico-pathologiques de la tumeur et la survie des patients atteints d'un cancer gastrique (196 cas)
Purposes Human intelectin-1 (ITLN-1) is a novel identified galactose-binding lectin that is expressed in the colonic goblet cells. Since gastric adenocarcinomas can arise through a process of intestinalization, we speculate that ITLN-1 may be aberrantly expressed in gastric cancer. This study was undertaken to examine the ITLN-1 expression in gastric cancer and correlate it with clinical outcomes. Methods One hundred and ninety-six gastric cancer patients were evaluated for the ITLN-1 expression by immunohistochemistry. The ITLN-1 transcripts were measured by real-time quantitative PCR. Results ITLN-1 expression was absent in normal gastric mucosa, whereas areas of intestinal metaplasia revealed ITLN-1 immunoreactivity. One hundred and forty-two gastric cancer patients (72.4%) were positive for ITLN-1 expression. In a subtotal of 20 patients, ITLN-1 transcripts were significantly enhanced in gastric cancer tissues than in normal gastric mucosa ( P < 0.001). The expression rate of ITLN-1 was higher in intestinal-type carcinomas than in diffuse-type carcinomas ( P = 0.003). ITLN-1 positivity in gastric cancer was positively correlated with tumor differentiation ( P = 0.001) and CDX2 expression ( P < 0.001), and inversely correlated with depth of invasion ( P = 0.007), lymph node metastasis ( P = 0.001), distant metastasis ( P = 0.014), clinical stage ( P = 0.006), Ki-67 expression ( P = 0.001), and heparanase expression ( P < 0.001), without correlation with age, gender, tumor location, or tumor size. In univariate and multivariate analyses, ITLN-1 was an independent prognostic factor for longer survival of gastric cancer patients ( P = 0.001). Conclusion The aberrant ITLN-1 expression in gastric cancer is correlated with clinicopathological features and may be a useful prognostic factor for predicting the outcomes of gastric cancer patients.
Journal of Cancer Research and Clinical Oncology , résumé, 2010